The Latest Breaking News from Lantern

Lyra Therapeutics Presents LYR-210 Positive Data from LANTERN Phase 2 Study for Chronic Rhinosinusitis

Lyra Therapeutics, Inc. (NASDAQ: LYRA) announced new data from its LANTERN Phase 2 study of LYR-210 in adult patients with chronic rhinosinusitis (CRS) at the 2022 Combined Otolaryngology Spring Meetings (COSM) being held in Dallas, Texas. 

Benzinga · Apr 29, 2022

Lantern Expands Cannabis Delivery In Massachusetts To South Shore

Cannabis e-commerce marketplace and home delivery platform Lantern plans to expand its delivery zone to Massachusetts' South Shore in partnership with economic empowerment retail and delivery licensee South Shore Buds, and adult-use retail dispensary Health Circle.

Benzinga · Feb 16, 2022

LTRN: Multiple Collaborations Illuminating Way Forward

By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT

Benzinga · Jan 20, 2022